Zymeworks Inc. Email Format

Biotechnology ResearchBritish Columbia, Canada201-500 Employees

Zymeworks is a mid-sized biotechnology company focused on developing therapies for cancers and autoimmune diseases that are difficult to treat. It advances a portfolio of differentiated biotherapeutics, including multispecific antibodies and antibody-drug conjugates, supported by its antibody-engineering platforms. The company also references Ziihera, a HER2-targeted bispecific antibody, as part of its ongoing programs and relies on an integrated research-and-development engine and collaborations to enable next-generation antibody therapeutics.

Based in Vancouver, British Columbia, the company operates within the biotechnology research industry and pursues partnerships and licenses to advance its programs. In 2026, Zymeworks launched Ziihera and entered exclusive development and commercialization agreements for zanidatamab with BeOne Medicines and Jazz Pharmaceuticals Ireland, expanding its partnership footprint. The company participates in industry events such as AACR to share updates on its research.

Get verified Zymeworks Inc. emails free

Company overview Employee directory